Neuroendocrine Carcinoma Clinical Trials

14 recruiting

Neuroendocrine Carcinoma Trials at a Glance

49 actively recruiting trials for neuroendocrine carcinoma are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 2 with 27 trials, with the heaviest enrollment activity in Shanghai, Houston, and Los Angeles. Lead sponsors running neuroendocrine carcinoma studies include National Cancer Institute (NCI), Suzhou Zelgen Biopharmaceuticals Co.,Ltd, and M.D. Anderson Cancer Center.

Browse neuroendocrine carcinoma trials by phase

Treatments under study

About Neuroendocrine Carcinoma Clinical Trials

Looking for clinical trials for Neuroendocrine Carcinoma? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neuroendocrine Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neuroendocrine Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 49 trials

Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 2Phase 3

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)189 enrolled244 locationsNCT05058651
Recruiting
Phase 2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8Metastatic Prostate Small Cell Neuroendocrine CarcinomaMetastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation+1 more
National Cancer Institute (NCI)30 enrolled13 locationsNCT05691465
Recruiting
Phase 1

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Neuroendocrine TumorsNeuroendocrine Carcinoma
Peter Hosein, MD36 enrolled1 locationNCT06889493
Recruiting
Phase 2

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Metastatic ChondrosarcomaLocally Advanced ChondrosarcomaMetastatic Sinonasal Adenocarcinoma+7 more
National Cancer Institute (NCI)40 enrolled1 locationNCT06176989
Recruiting

The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]

Neuroendocrine CarcinomaSmall Cell Lung Cancers
Samsung Medical Center797 enrolled6 locationsNCT02688894
Recruiting
Phase 2

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Pancreatic AdenocarcinomaPancreatic Neuroendocrine TumorGastrointestinal Neuroendocrine Tumor+4 more
University of Michigan Rogel Cancer Center66 enrolled3 locationsNCT05988918
Recruiting
Phase 1Phase 2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Cervical CancerMelanomaBladder Cancer+6 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Phase 2

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Neuroendocrine NeoplasmsSmall Cell Lung CarcinomaExtra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim204 enrolled59 locationsNCT05882058
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2

Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

Neuroendocrine Carcinomas (NEC)Neuroendocrine Carcinoma of PancreasNeuroendocrine Carcinoma of Prostate
Inkeun Park60 enrolled4 locationsNCT06893783
Recruiting
Phase 1Phase 2

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Large Cell Neuroendocrine CarcinomaLarge Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Molecular Partners AG138 enrolled3 locationsNCT07278479
Recruiting
Not Applicable

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Pancreatic Neuroendocrine TumorMedullary Thyroid CancerAdrenal Cortical Carcinoma+1 more
Shanghai Jiao Tong University School of Medicine21 enrolled1 locationNCT06141369
Recruiting
Phase 2

Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Sun Yat-sen University34 enrolled1 locationNCT07518602
Recruiting
Phase 1

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

Neuroendocrine TumorsCarcinoma, NeuroendocrineNeuroendocrine Carcinomas+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT06041516
Recruiting
Phase 1

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Large Cell Neuroendocrine Carcinoma of the LungSmall Cell Lung CarcinomaNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals116 enrolled5 locationsNCT07006727
Recruiting
Phase 2

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Neuroendocrine TumorsWell-Differentiated Neuroendocrine CarcinomaHigh Grade Neuroendocrine Carcinoma, Any Site
University of California, San Francisco29 enrolled1 locationNCT05746208
Recruiting
Phase 1Phase 2

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Advanced Neuroendocrine Carcinoma
Nanjing Leads Biolabs Co.,Ltd178 enrolled25 locationsNCT06157827
Recruiting

Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders

Pancreatic CancerPancreatic AdenocarcinomaPancreatic Neuroendocrine Carcinoma+5 more
Mayo Clinic20,000 enrolled3 locationsNCT00830557
Recruiting

Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix

Stage III Cervical Cancer AJCC v8Stage IIIA Cervical Cancer AJCC v8Stage IIIB Cervical Cancer AJCC v8+19 more
M.D. Anderson Cancer Center750 enrolled1 locationNCT04723095